Drug Profile
Research programme: metabolic and CNS disorder therapeutics - Censa Pharmaceuticals
Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator Censa Pharmaceuticals
- Class Neuroprotectants; Neuropsychotherapeutics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported CNS disorders; Metabolic disorders
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for research development in CNS-disorders in USA
- 28 Sep 2021 No recent reports of development identified for research development in Metabolic-disorders in USA
- 01 Jun 2020 Censa Pharmaceuticals has been acquired by PTC Therapeutics